Creating Effective Patient Engagement

 

Enhancing the Patient Experience

 

Capturing Patient Impact

 

Communicating Securely Within
a Trusted, Compliant Environment

TIESRx™ TreatmentAdvantage™

Communication Solution

Patients are seeking faster access to data and new technologies allowing easy to use, do-it-yourself platforms, and the information to help them take control of their health decisions.

Our Approach

TIESRx™ is a MedTech company with a revolutionary communication platform focused on reshaping the treatment experience.

Our person-centered model is designed to align incentives across all stakeholders with the goal of positively influencing healthcare outcomes while compressing avoidable healthcare costs.

The “key” differentiators for the TreatmentAdvantage™ communication solution:

  • Personalized Care Impact: Transforming patient-centricity to person-centricity through behavior based technology to support and drive actionable positive outcomes.
  • Social Needs for Value Based Care: Driving the advancement of care information by proactively engaging and efficiently integrating patient, caregiver, and support networks.
  • Identifying Broader Data Opportunity: Capturing real world consumerism (i.e. utilization/behavioral data) impactful to patient’s concordance with treatment decisions, compliance, and satisfaction.
  • Amplifying Impact with Data: Driving data insights on variables (i.e. decision drivers, risk points, interventions) that can amplify success of value based care.

Why Mobile Channel Optimization

Patients Become More Open to Sharing

If patients were able to communicate via email or text instead of phone only, they would become far more open.[1]

  • 51% of patients would feel less rushed when asking questions
  • 46% would feel more comfortable asking questions
  • 43% would reach out more often

Opportunity to Improve, Manage, and Educate Patients

There is evidence that connecting with patient’s through their smartphones provides an opportunity to improve care, manage health, and find information about a condition.

  • 88% of Americans are willing to share health information to improve care and treatment options.[2]
  • 66% of Americans are willing to use mobile apps to manage health.[3]
  • 62% of smartphone owners have used their phone in the past year to look up information about a health condition. [4]

Evidence Based

TIESRx™ TreatmentAdvantage™ Communication Solution framework is anchored on tenets of health behavior change constructs such as the health belief model, theory of planned behavior, and social cognitive theory. We are focused on empowering patients to make positive health decisions with the goal of fostering self-efficacy. The system is designed to influence outcomes by building positive behavior and actions. Timely and personalized feedback helps manage perceptions, beliefs, and expectations of patients.

Personalized For Each Patient

TIESRx™ TreatmentAdvantage™ Communication Solution has placed the patient and their treatment experience at the center of the application design. We focus our solution on reducing the discrepancies faced in real world patient outcomes. The path to attaining those validated positive outcomes rely on patients’ access to a comprehensive toolset that supports health literacy, adherence behavior, self-efficacy, and social support. We have built these tools with usability best practices to assure that patients have the best chance for an improved treatment experience and that they attain outcomes reflective of the treatment’s clinical trial impact.

Deep Knowledge of the Healthcare Landscape

TIESRx™ has 150+ years of collective experience working with patients, providers, payers, specialty pharmacies, and pharmaceutical companies. We have leveraged the expertise of our Chief Clinical Officer to assure that our solution is implemented to align with current clinical processes. We have paired our clinical expertise with our strong understanding of regulatory specifications to assure patients’ safety and privacy.

The Problem

When looking at patients’ medication adherence and attrition rates, disparities in the clinical environment versus the real world environment are a growing concern. Medication non-adherence compromises the efficacy of treatment program, reduces the impact the medication has on the condition, and diminishes the value of the treatment to patient outcomes.

Overcoming Universal Challenges

Today’s model takes a reactive approach to helping patients manage their treatment. Often, patients may not ask questions or are not able to understand driving non-compliant behavior. Patients must navigate the maze of healthcare resources resulting in confusion and a sense of overwhelming helplessness.

30-50% of treatment failures are caused by non-adherence every year[5].

38% loss of sales for the average pharmaceutical brand occur due to non-adherence issues[6].

There is evidence that medication adherence in real world compared to clinical trial is 20-50% lower within chronic[7], acute[8][9], and rare[10] diseases.

Attrition and drug-related discontinuation rates are 3-5x higher in the real world compared to the clinical trial environment.[11][12][13][14][15]

Confidence

TIESRx™ builds confidence with their understanding of pharma industry’s heavily regulated environment and significant requirements. TIESRx™ leverages best practices to ensure Compliance, Privacy, and Security.

Compliance

Compliance for medical health apps is a system that constantly shifts to the needs of technology and it’s users. PwC talks about the business of compliance, “The pharmaceutical and life sciences industry is among the most heavily regulated in the world. Today, these companies face unprecedented compliance challenges, and the close regulatory scrutiny to which they are subject is unlikely to abate anytime soon.[16]” They even assert that compliance, in all it’s complexity has become a market differentiator.

TIESRx™ has tackled compliance through a system that is able to flex with new regulation as well as the public’s concerns. We have ensured brand integrity meeting the FDA’s regulations for medical devices–CFR 820 requirements for GxP compliance. We have addressed both the February, 2015 FDA Mobile Medical Application Guidance requirements and the July, 2016 FDA General Wellness: Device Policy Guidance for the Industry.

Privacy

We know through our research that mobile health apps can severely fall short of delivering data privacy for their users through a comprehensive privacy policy. A study collecting and analyzing 211 Diabetes apps built for the android operating system found a lack of data security in 34% of the apps and a lack of standards in 30% of the apps to be the major barriers faced by the mHealth app market[17]. Another review of mHealth apps also notes that 81% of the 211 apps reviewed did not have privacy policies, and that of the 19% percent (41 apps) which did, not all of the provisions protected privacy[18].

TIESRx™ is committed to ensuring compliance with the privacy requirements in accordance with The Health Insurance Portability and Accountability Act (HIPAA) of 1996 via a comprehensive infrastructure of policies, procedures, and processes driven by an organizational culture to protect patients.

Security

The HITRUST Common Security Framework (CSF) was developed to address the multitude of security, privacy, and regulatory challenges facing healthcare organizations. By including federal and state regulations, standards and frameworks, and incorporating a risk-based approach, the CSF helps organizations address these challenges through a comprehensive and flexible framework of prescriptive and scalable security controls.

The HITRUST CSF includes, harmonizes, and cross-references existing, globally recognized standards, regulations, and business requirements, including HIPAA, HITECH, NIST, ISO, PCI, FTC, COBIT, and state laws.

TIESRx™ has implemented administrative, physical, technical and organizational safeguards to ensure compliance with HITECH requirements. We have leveraged a HITRUST environment for protecting ePHI (electronic protected health information) with additional safeguards that exceed legal and regulatory requirements for data exchange.

About Us

TIESRx™ has 150+ years of collective experience working with patients, providers, payers, specialty pharmacies, and pharmaceutical companies.

 

We are passionate about improving the patient experience.

 

Meet the Team

Footnotes   [ + ]

1. (2015). 564 report 20nov12.indd – Capgemini. Retrieved September 14, 2016, from https://www.capgemini.com/resource-file-access/resource/pdf/Estimated_Annual_Pharmaceutical_Revenue_Loss_Due_to_Medication_Non-Adherence.pdf.
2, 3, 4. (2016). The Digitally Empowered Patient | Makovsky. Retrieved September 14, 2016, from http://www.makovsky.com/news/the-digitally-empowered-patient/.
5. (2011). Medication Adherence Time Tool – American College of Preventive … Retrieved September 14, 2016, from http://www.acpm.org/?MedAdhereTTProviders.
6. (2015). 564 report 20nov12.indd – Capgemini. Retrieved September 14, 2016, from https://www.capgemini.com/resource-file-access/resource/pdf/Estimated_Annual_Pharmaceutical_Revenue_Loss_Due_to_Medication_Non-Adherence.pdf.
7. (2016). Late Breaking Abstracts – American Diabetes Association. Retrieved September 14, 2016, from http://diabetes.diabetesjournals.org/sites/default/files/ada/files/2016%20ADA%20LB%20Abstracts_HiRes%20FINAL%205%2011%2016.pdf.
8. (2015). Analysis of “Real World” Sovaldi® (sofosbuvir) Use and … – CVS Health. Retrieved September 14, 2016, from https://cvshealth.com/sites/default/files/styles/SovaldiUseAndDiscontinuation_ResearchArticle_PDF.pdf.
9. (2016). AHA: Poor real-world adherence to NOACs : Clinical Neurology News. Retrieved September 14, 2016, from http://www.clinicalneurologynews.com/specialty-focus/stroke/single-article-page/aha-poor-real-world-adherence-to-noacs/df5a89de27b5a7e2862199768698550a.html.
10, 11. Cooper, V. (2015). AdherenceResearchTM – Atlantis Healthcare. Retrieved from http://www.atlantishealthcare.com/uploads/images/stories/white-papers/Rare_Disease_White_Paper_SPREADS_final.pdf
12. (2016). Vertex Pharmaceuticals’ Cystic Fibrosis Drug Disappoints – WSJ. Retrieved September 14, 2016, from http://www.wsj.com/articles/vertex-pharmaceuticals-loss-narrows-as-sales-surge-1461792448.
13. (2015). New Hepatitis C Regimens Have Adherence Issues – Pharmacy Times. Retrieved September 14, 2016, from http://www.pharmacytimes.com/news/new-hepatitis-c-regimens-have-adherence-issues.
14. (2016). Real-World Study Gives Glimpse of How Two Oral MS Drugs Stack Up … Retrieved September 14, 2016, from https://consultqd.clevelandclinic.org/2016/06/real-world-study-gives-glimpse-two-oral-ms-drugs-stack/.
15. (2013). Poor Adherence to Oral Cancer Drugs a Growing Concern. Retrieved September 14, 2016, from http://www.ahdbonline.com/issues/2013/august-2013-vol-6-no-6-special-issue/1502-article-1502.
16. (2015). Regulatory risk & compliance in pharmaceutical & life sciences: PwC. Retrieved September 14, 2016, from http://www.pwc.com/us/en/health-industries/pharma-life-sciences/regulatory-risk-compliance.html.
17. Blenner, S. (2016). Privacy Policies of Android Diabetes Apps and Sharing of … – JAMA. Retrieved from http://jama.jamanetwork.com/article.aspx?articleid=2499265.
18. (2015). mHealth App Developer Economics 2014 – Research2Guidance. Retrieved September 14, 2016, from http://research2guidance.com/r2g/research2guidance-mHealth-App-Developer-Economics-2014.pdf.